Msac application 1173

MSAC Application 1173:

Final Decision Analytical Protocol (DAP) to guide the assessment of Epidermal Growth Factor Receptor (EGFR) gene mutation testing for eligibility

for erlotinib treatment as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

January 2012

Table of Contents

MSAC and PASC 3

Purpose of application 4

Background 4

Current arrangements for public reimbursement 4

Regulatory status 5

Intervention 7

Description of the disease 7

Delivery of the intervention 12

Prerequisites 13

Co-administered and associated interventions 15

Listing proposed and options for MSAC consideration 15

Proposed MBS listing 15

Clinical place for proposed intervention 19

Comparator 24

Outcomes for safety and effectiveness evaluation 24

Effectiveness 24

Comparison of test performance 24

Safety 25

Summary of PICO to be used for assessment of evidence (systematic review) 25

Clinical claim 28

Outcomes and health care resources affected by introduction of proposed intervention 29

Outcomes for economic evaluation 29

Health care resources 29

Proposed structure of economic evaluation (decision analysis) 34

References 35